

Electronic Acknowledgement Receipt	
EFS ID:	6472877
Application Number:	10590672
International Application Number:	
Confirmation Number:	2840
Title of Invention:	Methods for Inhibiting Tumor Cell Growth
First Named Inventor/Applicant Name:	Andrew Kung
Correspondence Address:	Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky and Popeo One Financial Center - Boston MA 02111 US - -
Filer:	Cynthia A. Kozakiewicz/Donna Doyle
Filer Authorized By:	Cynthia A. Kozakiewicz
Attorney Docket Number:	20363-025 NATL
Receipt Date:	17-NOV-2009
Filing Date:	23-OCT-2007
Time Stamp:	18:45:02
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 180

RAM confirmation Number		5819			
Deposit Account					
Authorized User					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	20363_025NATL_Transmittal.pdf	78272	no	1
			a6f01cc47c7917333c41bb9e8726e2cb0a887529		
Warnings:					
Information:					
2	Transmittal Letter	20363_025NATL_SIDS.pdf	90196	no	2
			fe554742cf4c924d8c4d3814aa7eff72e857cfa5		
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Filed (SB/08)	20363_025NATL_1449.pdf	200367	no	4
			840b4ff4473f186260016593a8b0979e0b13b9e9		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
4	NPL Documents	Arcaro.pdf	44724	no	2
			5ff443f9c2f6d2547bb47cfdf7477ba9f6f2bb7e7		
Warnings:					
Information:					
5	NPL Documents	Capraro_Synthesis.pdf	127273	no	1
			61d86d59adf870e28b371d6bb84dddb0923a9dce		
Warnings:					
Information:					
6	NPL Documents	Ferreira_Brandao_Guerreiro.pdf	59024	no	1
			da5ca7e79a8e8034cb8ebb325b554cf727219012		
Warnings:					
Information:					
7	NPL Documents	Garcia_Echeverria_Discovery_Potent.pdf	63117	no	1
			064e70c223f30f93d35461badb6c37f5874d57f1		
Warnings:					
Information:					

8	NPL Documents	Garcia_Echeverria_Targeted_Anti_Cancer.pdf	136666	no	2
			21d47c5674758dfea7739931bbc2bf1cdc4de343		
Warnings:					
Information:					
9	NPL Documents	Garcia_Echeverria_In_Vivo_Cancer_Cell.pdf	205497	no	9
			ae2473a42200dc930eed636e651944eecd75c		
Warnings:					
Information:					
10	NPL Documents	Garcia_Echeverria_NVP_AEW541_Novel_TargetedI.pdf	112128	no	1
			56744d6ec3610895876d405a2e87e3079903c3c9		
Warnings:					
Information:					
11	NPL Documents	Krystal_IGF-1R.pdf	211269	no	1
			5d0b1335abc9eea839865e8eb0b5751508ee08c8		
Warnings:					
Information:					
12	NPL Documents	Krystal_small_molecule.pdf	306764	no	2
			8d61e7885f72dfed6fc13aa8612031b40593452d		
Warnings:					
Information:					
13	NPL Documents	Mitsiades1.pdf	295968	no	2
			c0352bf6c3f1ae44be58726ce84104edae91aa20		
Warnings:					
Information:					
14	NPL Documents	Mitsiades2.pdf	164876	no	1
			25769e5afba861936f21128be045fda5520a462d		
Warnings:					
Information:					
15	NPL Documents	Mitsides3.pdf	374727	no	2
			f010dbc5b742c2e7f5d4f7ab31c68a2b7f313542		
Warnings:					
Information:					
16	NPL Documents	OReilly_Abrogation_EurJCancer.pdf	150557	no	1
			6a8457f5d87f6173f4f68a102e633f50bbde4751		
Warnings:					
Information:					

17	NPL Documents	Schnell_Characterization.pdf	259935	no	2
			0c6d71633e9a2da5378553f57f3cc78ff8b3c1f		
Warnings:					
Information:					
18	NPL Documents	Scotlandi_Effectiveness_EurJCancer.pdf	149400	no	1
			8b341486142a01543b7430bc2c95e45e91f812dc		
Warnings:					
Information:					
19	NPL Documents	Warshamana_Greene_Insulin_Like.pdf	1911610	no	9
			e17d08ccee66639b283efa7c4fec8fcf804640b5		
Warnings:					
Information:					
20	NPL Documents	Warshamana_Greene_Novel_IGF-1R.pdf	257795	no	2
			e5c0e61ce843d16cacb26f928ca4a7d596d1b3fa		
Warnings:					
Information:					
21	NPL Documents	Warshamana_Greene_Mol_Cancer.pdf	409126	no	9
			5d64c3df78f90d31e178dd3e9c3c3b7c1553da49		
Warnings:					
Information:					
22	NPL Documents	Zhao_IGF_1_EurJCancer.pdf	147279	no	1
			8fee01b5132e9a5a0eaa318af7aaec112052b1fb		
Warnings:					
Information:					
23	NPL Documents	Inhibitors.pdf	294480	no	2
			7c51f736ecd2dbe84f0e655944d61172bc71c60e		
Warnings:					
Information:					
24	NPL Documents	Mitsiades4.pdf	94307	no	2
			4f5a724b40cf23c6b5f246210919d49e43821ce9		
Warnings:					
Information:					
25	Fee Worksheet (PTO-875)	fee-info.pdf	30265	no	2
			5065bed281a4cd32d0fc2eb06271b56a25142dc4		
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.